Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Novartis
UroGen Pharma Ltd.
Poseida Therapeutics, Inc.
AO GENERIUM
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Celldex Therapeutics
Celldex Therapeutics